Clinical Trial Update: A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TPST-1120 in combination with atezolizumab and bevacizumab for unresectable or metastatic hepatocellular carcinoma in patients who have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• TPST-1120 (TPST-1120)

Snippet

Sponsor: Tempest Therapeutics | Conditions: Hepatocellular Carcinoma (HCC) | Phase 3 | Status: NOT_YET_RECRUITING